Adverse effect: any · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether VITAMIN E changes adverse effect: any compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether VITAMIN E changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
NORADRENERGIC DRUGS may leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (low certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
DOPAMINERGIC DRUGS may leads to lower tardive dyskinesia: No clinically important improvement compared with PLACEBO (low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes tardive dyskinesia: Deterioration compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse events ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
General mental state: Deterioration · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes general mental state: Deterioration compared with PLACEBO (very low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether NORADRENERGIC DRUGS changes tardive dyskinesia: deterioration compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse events ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Mental state ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether NORADRENERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
No improvement in quality of life · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether NORADRENERGIC DRUGS changes no improvement in quality of life compared with PLACEBO (very low certainty).
1 finding from 1 review
Tranquillisation or asleep · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ needing additional injections during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes repeated need for tranquillisation ‐ needing additional injections… compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes specific behaviour: Agitation ‐ clinically important change (PANSS… compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Global state: non‐responders to the first injection · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) may leads to lower global state: non‐responders to the first injection compared with PLACEBO/NIL (low certainty).
1 finding from 1 review